COPD & Emphysema Support Group
COPD is a progressive disease characterized by airflow obstruction or limitation. Emphysema is characterized by loss of elasticity of the lung tissue, destruction of structures supporting the alveoli and of capillaries feeding the alveoli. Both have symptoms that include shortness of breath, among other respiratory troubles. If you are a COPD or Emphysema sufferer, join...
Formoterol is an effective and safe drug in the treatment of COPD, according to a recent study.
Chronic Obstructive Pulmonary Disease (COPD) is a lung condition wherein the patient suffers from symptoms of breathlessness, cough and reduced exercise capacity. Drugs that dilate the bronchi (the branches of the airways) are used to relieve the obstruction and help the patient to breathe. These drugs may be short-acting like salbutamol, or long-acting like salmeterol and formoterol.
The effects of formoterol and placebo in COPD patients were compared in a study recently published in BMC Pulmonary Medicine. The aim of the study was to establish the usefulness of the long-acting drug in COPD as well as to test its safety in COPD patients. Some prior studies had suggested that long-acting bronchodilators could increase the risk of death in these patients.
The study was carried out on a total of 613 patients of European and Japanese origin. Some patients received 4.5g of formoterol twice daily, others received a doubled dose of 9g of formoterol twice daily, and still others received a placebo (an inert substance for comparison purpose). The patients were administered the drug for a total duration of 12 weeks. Lung function was measured using a spirometer. Patients who needed additional medication could take the short-acting drug salbutamol whenever required. They could also continue to take short-acting anticholinergics as earlier.
At the end of the study period, it was found that the measured lung function (which was FEV1 60-min post-dose in the study) improved significantly in both the formoterol groups as compared to placebo. There was no significant difference between the two formoterol groups.
The improvement in clinically-relevant quality of life, as measured by a questionnaire, was significantly higher with formoterol 9g as compared to placebo. However, there was no clinically-significant improvement in quality of life with 4.5g formoterol as compared to placebo. Both groups on formoterol required less additional salbutamol treatment as compared to placebo; the group on the higher dose also required less salbutamol rescue as compared to the lower dose.
Most side effects in patients with formoterol were similar in number as compared to placebo. Side effects included nasopharyngitis (inflammation of the nose and throat), COPD exacerbation, and bronchitis complication. Two deaths occurred in the formoterol groups, but they were unrelated to the treatment.
Thus, formoterol is an effective drug in improving COPD at doses of 4.5g as well as 9g twice a day, with the twice daily dose of 9g providing some additional benefits. Thus, the study refutes the conclusions of some earlier studies which state that formoterol treatment can cause more deaths in COPD patients.
Reference:
1. Bogdan MA, Aizawa H, Fukuchi Y, Mishima M, Nishimura M, Ichinose M. Efficacy and safety of inhaled formoterol 4.5 and 9 g twice daily in Japanese and European COPD patients: Phase III study results. BMC Pulmonary Medicine 2011, 11:51 doi:10.1186/1471-2466-11-51
Read more: Formoterol is Effective and Safe in Patients With COPD | MedIndia http://www.medindia.net/news/healthinfocus/Formoterol-is-Effective-and-Safe-in-Patients-With-COPD-94200-1.htm#ixzz1fTseo5EN
Thought some of you might be interested in this.
Love Holly
Chronic Obstructive Pulmonary Disease (COPD) is a lung condition wherein the patient suffers from symptoms of breathlessness, cough and reduced exercise capacity. Drugs that dilate the bronchi (the branches of the airways) are used to relieve the obstruction and help the patient to breathe. These drugs may be short-acting like salbutamol, or long-acting like salmeterol and formoterol.
The effects of formoterol and placebo in COPD patients were compared in a study recently published in BMC Pulmonary Medicine. The aim of the study was to establish the usefulness of the long-acting drug in COPD as well as to test its safety in COPD patients. Some prior studies had suggested that long-acting bronchodilators could increase the risk of death in these patients.
The study was carried out on a total of 613 patients of European and Japanese origin. Some patients received 4.5g of formoterol twice daily, others received a doubled dose of 9g of formoterol twice daily, and still others received a placebo (an inert substance for comparison purpose). The patients were administered the drug for a total duration of 12 weeks. Lung function was measured using a spirometer. Patients who needed additional medication could take the short-acting drug salbutamol whenever required. They could also continue to take short-acting anticholinergics as earlier.
At the end of the study period, it was found that the measured lung function (which was FEV1 60-min post-dose in the study) improved significantly in both the formoterol groups as compared to placebo. There was no significant difference between the two formoterol groups.
The improvement in clinically-relevant quality of life, as measured by a questionnaire, was significantly higher with formoterol 9g as compared to placebo. However, there was no clinically-significant improvement in quality of life with 4.5g formoterol as compared to placebo. Both groups on formoterol required less additional salbutamol treatment as compared to placebo; the group on the higher dose also required less salbutamol rescue as compared to the lower dose.
Most side effects in patients with formoterol were similar in number as compared to placebo. Side effects included nasopharyngitis (inflammation of the nose and throat), COPD exacerbation, and bronchitis complication. Two deaths occurred in the formoterol groups, but they were unrelated to the treatment.
Thus, formoterol is an effective drug in improving COPD at doses of 4.5g as well as 9g twice a day, with the twice daily dose of 9g providing some additional benefits. Thus, the study refutes the conclusions of some earlier studies which state that formoterol treatment can cause more deaths in COPD patients.
Reference:
1. Bogdan MA, Aizawa H, Fukuchi Y, Mishima M, Nishimura M, Ichinose M. Efficacy and safety of inhaled formoterol 4.5 and 9 g twice daily in Japanese and European COPD patients: Phase III study results. BMC Pulmonary Medicine 2011, 11:51 doi:10.1186/1471-2466-11-51
Read more: Formoterol is Effective and Safe in Patients With COPD | MedIndia http://www.medindia.net/news/healthinfocus/Formoterol-is-Effective-and-Safe-in-Patients-With-COPD-94200-1.htm#ixzz1fTseo5EN
Thought some of you might be interested in this.
Love Holly
-
My 6mo twin DD's are EBF and just started rice cereal on the first. Everything has been going fine except this morning one of them had a diaper rash (lots of redness around her anus). I read this as one of the signs of an allergy. BUT I did just buy a different brand diaper yesterday (which they have used randomly before w/no issues). Do you think its the cereal or the diaper? Im ready to start...
Easy Breathing to you, and to everyone here.
Love
Holly
I use formoterol as part of my medications. My dose is 12 micrograms, which I take in the morning, it bronchodilates for about 12 hours. I've tried the 6 micrograms during summer months but find it doesn't work so well for me.
Initially my doc prescribed twice daily but I find 2 doses of 12 mcg gave me a lot of cramps, just the one dose daily is fine tho and I can manage on that.
I will investigate the 9mcg dose for summer time I think.
I think its always worth checking with the doc to see if they think the medicine is compatible with your other medicines and health conditions.
Thanks for posting this Holly, its interesting.